Cargando…

Risk of genital and urinary tract infections associated with SGLT‐2 inhibitors as an add‐on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea

Sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors are antidiabetic drugs with associated safety concerns regarding the risk of genital and urinary tract infections. This study assessed the risk of genital and urinary tract infections associated with prescription of SGLT‐2 inhibitors as an add‐on th...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Hyeri, Choi, Eunmi, Park, Eunjun, Na, Eonji, Chung, Soo Youn, Kim, Bonggi, Han, Soon Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8929338/
https://www.ncbi.nlm.nih.gov/pubmed/35005849
http://dx.doi.org/10.1002/prp2.910
_version_ 1784670843052228608
author Yang, Hyeri
Choi, Eunmi
Park, Eunjun
Na, Eonji
Chung, Soo Youn
Kim, Bonggi
Han, Soon Young
author_facet Yang, Hyeri
Choi, Eunmi
Park, Eunjun
Na, Eonji
Chung, Soo Youn
Kim, Bonggi
Han, Soon Young
author_sort Yang, Hyeri
collection PubMed
description Sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors are antidiabetic drugs with associated safety concerns regarding the risk of genital and urinary tract infections. This study assessed the risk of genital and urinary tract infections associated with prescription of SGLT‐2 inhibitors as an add‐on therapy to metformin in patients with type 2 diabetes mellitus (T2DM) compared to dipeptidyl peptidase‐4 (DPP‐4) inhibitors, sulfonylurea (SU), and thiazolidinedione (TZD). We conducted a retrospective cohort study using the NHIS—National Health Insurance—Database in Korea from 2014 to 2017. Patients aged ≥19 years and those diagnosed with T2DM prior to drug prescription were enrolled. The outcomes were genital and urinary tract infections. Analysis was performed using Cox's proportional hazard model following 1:1 propensity score matching to calculate the hazard ratio (HR) with a 95% confidence interval (CI). Among the 107 131 patients included in the study, a total of 7738, 7145, and 2175 patients were assigned to the DPP‐4 inhibitors, SU, and TZD comparator groups, using the propensity score (PS) of each comparator based on 7741 people in the assessed drug SGLT‐2 inhibitor group. SGLT‐2 inhibitors were associated with a higher risk of genital infections than DPP‐4 inhibitors (HR: 2.39, 95% CI: 2.07–2.76), SU (HR: 3.23, 95% CI: 2.73–3.81), and TZD (HR: 3.23, 95% CI: 2.35–4.44), as an add‐on therapy to metformin. Similar results were observed for the risk of urinary tract infections. In conclusion, SGLT‐2 inhibitors are significantly associated with a higher risk of genital and urinary tract infections compared to DPP‐4 inhibitors, SU, and TZD.
format Online
Article
Text
id pubmed-8929338
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-89293382022-03-24 Risk of genital and urinary tract infections associated with SGLT‐2 inhibitors as an add‐on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea Yang, Hyeri Choi, Eunmi Park, Eunjun Na, Eonji Chung, Soo Youn Kim, Bonggi Han, Soon Young Pharmacol Res Perspect Invited Reviews Sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors are antidiabetic drugs with associated safety concerns regarding the risk of genital and urinary tract infections. This study assessed the risk of genital and urinary tract infections associated with prescription of SGLT‐2 inhibitors as an add‐on therapy to metformin in patients with type 2 diabetes mellitus (T2DM) compared to dipeptidyl peptidase‐4 (DPP‐4) inhibitors, sulfonylurea (SU), and thiazolidinedione (TZD). We conducted a retrospective cohort study using the NHIS—National Health Insurance—Database in Korea from 2014 to 2017. Patients aged ≥19 years and those diagnosed with T2DM prior to drug prescription were enrolled. The outcomes were genital and urinary tract infections. Analysis was performed using Cox's proportional hazard model following 1:1 propensity score matching to calculate the hazard ratio (HR) with a 95% confidence interval (CI). Among the 107 131 patients included in the study, a total of 7738, 7145, and 2175 patients were assigned to the DPP‐4 inhibitors, SU, and TZD comparator groups, using the propensity score (PS) of each comparator based on 7741 people in the assessed drug SGLT‐2 inhibitor group. SGLT‐2 inhibitors were associated with a higher risk of genital infections than DPP‐4 inhibitors (HR: 2.39, 95% CI: 2.07–2.76), SU (HR: 3.23, 95% CI: 2.73–3.81), and TZD (HR: 3.23, 95% CI: 2.35–4.44), as an add‐on therapy to metformin. Similar results were observed for the risk of urinary tract infections. In conclusion, SGLT‐2 inhibitors are significantly associated with a higher risk of genital and urinary tract infections compared to DPP‐4 inhibitors, SU, and TZD. John Wiley and Sons Inc. 2022-01-10 /pmc/articles/PMC8929338/ /pubmed/35005849 http://dx.doi.org/10.1002/prp2.910 Text en © 2022 The Authors. Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Invited Reviews
Yang, Hyeri
Choi, Eunmi
Park, Eunjun
Na, Eonji
Chung, Soo Youn
Kim, Bonggi
Han, Soon Young
Risk of genital and urinary tract infections associated with SGLT‐2 inhibitors as an add‐on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea
title Risk of genital and urinary tract infections associated with SGLT‐2 inhibitors as an add‐on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea
title_full Risk of genital and urinary tract infections associated with SGLT‐2 inhibitors as an add‐on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea
title_fullStr Risk of genital and urinary tract infections associated with SGLT‐2 inhibitors as an add‐on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea
title_full_unstemmed Risk of genital and urinary tract infections associated with SGLT‐2 inhibitors as an add‐on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea
title_short Risk of genital and urinary tract infections associated with SGLT‐2 inhibitors as an add‐on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea
title_sort risk of genital and urinary tract infections associated with sglt‐2 inhibitors as an add‐on therapy to metformin in patients with type 2 diabetes mellitus: a retrospective cohort study in korea
topic Invited Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8929338/
https://www.ncbi.nlm.nih.gov/pubmed/35005849
http://dx.doi.org/10.1002/prp2.910
work_keys_str_mv AT yanghyeri riskofgenitalandurinarytractinfectionsassociatedwithsglt2inhibitorsasanaddontherapytometformininpatientswithtype2diabetesmellitusaretrospectivecohortstudyinkorea
AT choieunmi riskofgenitalandurinarytractinfectionsassociatedwithsglt2inhibitorsasanaddontherapytometformininpatientswithtype2diabetesmellitusaretrospectivecohortstudyinkorea
AT parkeunjun riskofgenitalandurinarytractinfectionsassociatedwithsglt2inhibitorsasanaddontherapytometformininpatientswithtype2diabetesmellitusaretrospectivecohortstudyinkorea
AT naeonji riskofgenitalandurinarytractinfectionsassociatedwithsglt2inhibitorsasanaddontherapytometformininpatientswithtype2diabetesmellitusaretrospectivecohortstudyinkorea
AT chungsooyoun riskofgenitalandurinarytractinfectionsassociatedwithsglt2inhibitorsasanaddontherapytometformininpatientswithtype2diabetesmellitusaretrospectivecohortstudyinkorea
AT kimbonggi riskofgenitalandurinarytractinfectionsassociatedwithsglt2inhibitorsasanaddontherapytometformininpatientswithtype2diabetesmellitusaretrospectivecohortstudyinkorea
AT hansoonyoung riskofgenitalandurinarytractinfectionsassociatedwithsglt2inhibitorsasanaddontherapytometformininpatientswithtype2diabetesmellitusaretrospectivecohortstudyinkorea